BerandaBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
$55,27
Setelah Jam Perdagangan Normal:(0,00%)0,00
$55,27
Tutup: 15 Apr, 16.02.08 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$55,47
Rentang hari
$54,99 - $56,05
Rentang tahun
$50,76 - $66,28
Kapitalisasi pasar
10,63Â M USD
Volume Rata-Rata
1,91Â jt
Rasio P/E
30,63
Hasil dividen
-
Bursa utama
NASDAQ
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 874,56Â jt | 17,03% |
Biaya operasional | 329,01Â jt | 19,09% |
Penghasilan bersih | -46,57Â jt | -137,28% |
Margin laba bersih | -5,33 | -131,88% |
Penghasilan per saham | 0,46 | -50,00% |
EBITDA | 209,68Â jt | 13,33% |
Tarif pajak efektif | -71,52% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,56Â M | 37,17% |
Total aset | 7,59Â M | 8,66% |
Total liabilitas | 1,51Â M | 13,23% |
Total ekuitas | 6,09 M | — |
Saham yang beredar | 192,32 jt | — |
Harga terhadap nilai buku | 1,75 | — |
Tingkat pengembalian aset | 6,46% | — |
Tingkat pengembalian modal | 7,34% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -46,57Â jt | -137,28% |
Kas dari operasi | 99,64Â jt | -46,32% |
Kas dari investasi | -42,45Â jt | -155,56% |
Kas dari pembiayaan | 3,16Â jt | 10,42% |
Perubahan kas bersih | 61,57Â jt | -76,97% |
Arus kas bebas | 88,74Â jt | 13,56% |
Tentang
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Didirikan
Mar 1997
Kantor pusat
Situs
Karyawan
3.221
